MARKET

INDP

INDP

Indaptus Therapeutics Inc
NASDAQ
1.230
-0.100
-7.52%
After Hours: 1.160 -0.07 -5.69% 19:22 05/20 EDT
OPEN
1.370
PREV CLOSE
1.330
HIGH
1.380
LOW
1.200
VOLUME
517.34K
TURNOVER
--
52 WEEK HIGH
19.91
52 WEEK LOW
1.200
MARKET CAP
139.29M
P/E (TTM)
-0.0570
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INDP last week (0511-0515)?
Weekly Report · 2d ago
Indaptus Therapeutics GAAP EPS of -$0.23
Seeking Alpha · 5d ago
Earnings Scheduled For May 15, 2026
Benzinga · 5d ago
Indaptus Therapeutics Q1 EPS $(0.23) Beats $(1.87) Estimate
Benzinga · 5d ago
Indaptus Therapeutics Q1 net loss narrows as expenses fall
Reuters · 5d ago
Indaptus net loss narrows to $2.5 million in Q1 FY26; R&D expenses drop 82% to $491,134
PUBT · 5d ago
INDAPTUS THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 5d ago
Weekly Report: what happened at INDP last week (0504-0508)?
Weekly Report · 05/11 10:14
More
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Webull offers Indaptus Therapeutics Inc stock information, including NASDAQ: INDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INDP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INDP stock methods without spending real money on the virtual paper trading platform.